Wilmington-based drug development firm AAIPharma has expanded its overseas operations with the addition of a seven-person staff in Budapest, Hungary. The Eastern European opening earlier in November comes on the heels of an office opening in South Africa.
AAIPharma, with established operations in Croatia and Russia, now has operations in 14 countries worldwide.
"Central and Eastern Europe is one of most dynamic regions to run clinical trials," said Ludo Reynders. Ph.D., AAIPharma president and CEO. "Hungary with its population of ten million, good hospital infrastructure and the availability of patients is recognised as a key country in this region."
"As the needs of our biotechnology and pharmaceutical customers to run global clinical trials are ever increasing, it is important that we continue to expand our international presence in key regions such as this to meet these demands."
The group in Hungary has therapeutic expertise in the areas of oncology, cardiovascular, respiratory, gastrointestinal and anti-infective clinical trials, along with particular specialist knowledge of paediatric trials. They will provide clinical monitoring, project management and regulatory affairs services across Phase II-IV.